エピソード

  • Silver Range identifies new drill targets at East Goldfield property in Nevada

    Silver Range identifies new drill targets at East Goldfield property in Nevada
    2026/11/11
    Silver Range Resources CEO Mike Power joined Steve Darling from Proactive to discuss results from a three-dimensional induced polarization (3D-IP) and resistivity survey at the company’s East Goldfield Property in Nye County, Nevada. The survey identified a large zone of elevated chargeability associated with surface lithocap and ledge-style epithermal high-sulphidation mineralization. The inverted chargeability and resistivity data are considered reliable to depths of approximately 250 to 500 metres below surface, depending on the geometry of the source bodies. Conducted across the western portion of the property, the survey outlined an anomaly interpreted to define the limits of a high-sulphidation mineralized system, or cell. The anomaly encompasses the historic Tom Keane Mine as well as a drill target identified through historical drilling in the immediate mine area. Power told Proactive that the company's primary target lies northwest of the Tom Keane Mine and its associated historical drill target. The area is characterized by faulted and intensely alunite-altered pyroclastic rocks of the Milltown Andesite. The geological setting is significant because the Milltown Andesite hosts high-grade high-sulphidation gold mineralization in the Goldfield Main district, located approximately eight kilometres west of East Goldfield along a shared structural corridor. Silver Range plans to use the survey results to advance the target toward drilling. The company intends to design and obtain permits for a drill program to test the core target. #proactiveinvestors #silverrangeresources #tsxv #sng #mining #GoldExploration #Nevada #EastGoldfield #Goldfield #GoldMining #InducedPolarization #Geophysics #MineralExploration #Mining
    続きを読む 一部表示
    5 分
  • Medicus Pharma shares rationale as CD228V becomes lead development priority

    Medicus Pharma shares rationale as CD228V becomes lead development priority
    2026/11/11
    Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company's third-quarter 2026 financial results, which showed a narrower net loss and lower general and administrative expenses as Medicus shifts its development focus towards CD228V, an antibody-drug conjugate licensed from Pfizer. For the three months ended September 30, 2026, Medicus reported a net loss of $15.2 million, or $11.64 per share, compared with a loss of $16 million, or $56.18 per share, in the same period last year. Medicus ended the quarter with $13.1 million in cash, cash equivalents and restricted cash, including $5 million in unrestricted cash and cash equivalents. Bokhari said the third quarter marked a transformation for Medicus into a precision oncology-focused biotechnology company, with CD228V now its principal development priority. Medicus holds an exclusive worldwide licence to develop, manufacture and commercialize CD228V through a co-development agreement with Pfizer, which has provided $2 million in development funding. The company is targeting initial clinical proof-of-concept in patients with relapsed, refractory or immunotherapy-resistant melanoma. The program is supported by an existing US investigational new drug application and a first-in-human Phase 1 study. Medicus believes CD228V could potentially achieve an objective response rate above 30% in melanoma, although that target has yet to be demonstrated in clinical trials. Pfizer also has the option to fund all or part of development costs beginning with the first pivotal trial. Medicus is also advancing plans to separate its SkinJect business through a proposed business combination with a special purpose acquisition company. Meanwhile, for Teverelix, the company has submitted a proposed seamless Phase 2b/3 clinical trial protocol to the US Food and Drug Administration for advanced prostate cancer. The study is designed to enrol approximately 608 patients, subject to meeting predefined criteria to proceed. Rather than fund the Teverelix study itself, Medicus intends to pursue an out-licensing agreement or another strategic partnership to advance the program. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #CD228V #PrecisionOncology #Biotechnology #CancerResearch #Melanoma #Pfizer #SkinJect #Teverelix #ClinicalTrials #Pharma
    続きを読む 一部表示
    9 分
  • Meren CEO outlines Nigerian drilling push after strong quarter

    Meren CEO outlines Nigerian drilling push after strong quarter
    2026/11/12
    Meren Energy Inc (TSX:MER, STO:MER, OTCQX:MRNFF) CEO Dr Oliver Quinn spoke with Proactive's Stephen Gunnion about strong third-quarter financial results, renewed drilling activity in Nigeria and plans to accelerate operations during 2027. Meren reported quarterly EBITDA of more than $110 million and free cash flow of $59 million, with higher commodity prices supporting performance. Cumulative EBITDA for the first nine months also exceeded the company's full-year 2025 total, despite slightly lower production. Quinn explained that Meren's return to drilling follows an 18-month pause, which allowed its joint venture to assess new subsurface data and complete engineering work. A rig is now testing exploration potential before moving on to infill wells aimed at supporting near-term production. Further activity is planned at another Nigerian field, with two rigs expected to be operating during 2027. The CEO also discussed opportunities to appraise discovered resources and connect them to existing infrastructure, alongside the company's disciplined approach to capital allocation. Meren reduced net debt by approximately $27 million during the quarter, maintained net debt to EBITDA at around 0.5 times and reported liquidity above $300 million. Quinn outlined how the company intends to balance investment in production growth with financial resilience and the potential for rapid returns from infill drilling and well workovers. For more oil and gas company interviews, energy market updates and investor insights, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy #Meren #OilAndGas #NigeriaOil #OliverQuinn #OilProduction #NigeriaEnergy #OilExploration #OilDrilling #EnergyStocks #EBITDA #FreeCashFlow #EnergyInvestment #OilAndGasInvesting #ProactiveInvestors
    続きを読む 一部表示
    5 分
  • Pennpetro Energy targets European pellet market after first commercial ICE shipment to Poland

    Pennpetro Energy targets European pellet market after first commercial ICE shipment to Poland
    2026/11/11
    Pennpetro Energy plc (LSE:PPP) executive co-chairman and president of ICE Holdings Richard Spinks spoke with Proactive's Stephen Gunnion about the first commercial production of ICE black pellets, initial shipments to Poland and plans to expand capacity. Spinks said the first full production run was completed on October 29, with the pellets bagged and shipped to Poland. A test container has arrived and is being divided between pellet stove and boiler manufacturers for testing. The shipment has also helped confirm logistics, delivery times and costs, with door-to-door delivery taking around 30 days. Poland is the initial target market, with more than 450,000 households using pellet heating and annual demand estimated at two million tonnes. Spinks sees scope for growth as domestic supply struggles to keep pace. He also outlined plans for production facilities in Nova Scotia and Newfoundland and Labrador, each with potential capacity of 50,000 tonnes a year. The interview covered the proposed reverse takeover involving Pennpetro and ICENERGY, which remains subject to shareholder and regulatory approval, and the next commercial milestones for the business. Visit Proactive’s YouTube channel for more company interviews and updates. Give this video a like, subscribe to the channel and enable notifications so you don't miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #PennpetroEnergy #ICEBlackPellets #Biomass #RenewableEnergy #EnergyTransition #WoodPellets #PelletFuel #EuropeanEnergyMarket #Poland #CleanEnergy #EnergyInvesting #ProactiveInvestors
    続きを読む 一部表示
    11 分
  • Retirement investing: how portfolios are changing

    Retirement investing: how portfolios are changing
    2026/11/12
    Investment Markets CEO Darren Connolly talked with Proactive about how retirement is changing the way Australian investors construct portfolios, with a growing shift away from higher-growth strategies towards income, stability and capital preservation. Connolly explained that investors in their 20s, 30s and 40s have traditionally focused on growing their portfolios and have generally been more willing to accept risk because of their longer investment timeframes. As more baby boomers move into retirement, however, Investment Markets is seeing a significant change in the types of opportunities investors are researching. He said fixed-income opportunities have become increasingly important as interest rates have risen, bringing bonds back into consideration after years of very low yields. Interest in private credit, mortgage funds and other fixed-interest investments has also grown, with income-focused categories now accounting for close to half of traffic on the Investment Markets platform. Connolly also highlighted sequencing risk as an important but often poorly understood issue for retirees. A significant market decline around the time an investor begins withdrawing from superannuation can reduce the capital available to participate in a subsequent market recovery, potentially shortening the longevity of retirement savings. Connolly’s message to retirees was to remain informed and actively understand how portfolios are structured, even when working with an adviser. Visit Proactive’s YouTube channel for more interviews and market insights. Don’t forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #InvestmentMarkets #RetirementInvesting #RetirementPlanning #PortfolioConstruction #SequencingRisk #FixedIncome #PrivateCredit #MortgageFunds #ETFs #Superannuation #IncomeInvesting #InvestmentStrategy #AustralianInvestors #RetirementIncome #Investing
    続きを読む 一部表示
    12 分
  • First Graphene targets growth in US defence market

    First Graphene targets growth in US defence market
    2026/11/12
    First Graphene Ltd managing director and CEO Michael Bell talked with Proactive about three new orders worth a combined A$45,000, including a repeat PureGRAPH order for a US defence application and the company’s first commercial orders for its newly developed graphene oxide product. Bell said the US defence customer had been growing its demand over time, with the latest order reaching a level that First Graphene considered significant enough to highlight. He said the wider defence segment could represent an important longer-term opportunity for the company, particularly as graphene applications continue to develop across composites and carbon fibre. The two graphene oxide orders also represent First Graphene’s first sales of the material. Bell explained that the product was developed using the company’s electrochemical exfoliation process and opens opportunities with two new customers. Potential applications discussed in the interview included electronics, where graphene can support electrical and thermal conductivity, as well as construction materials. Bell highlighted opportunities across phones, laptops, GPUs for data centres, cement and concrete, gypsum wallboards, polymer coatings and anti-corrosion coatings. Looking ahead, Bell said investors should watch developments in cement and concrete, particularly in the UK and Europe, alongside the carbon-fibre composite segment. He said First Graphene had made performance breakthroughs in carbon fibre and was seeing an increasing number of addressable opportunities, with potential applications extending into defence and aerospace. Visit Proactive’s YouTube channel for more interviews and company updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future content. #FirstGraphene #PureGRAPH #Graphene #GrapheneOxide #AdvancedMaterials #USDefence #DefenceTechnology #CarbonFibre #Composites #ConstructionMaterials #Cement #Concrete #Electronics #ThermalManagement #Aerospace #ASXFGR
    続きを読む 一部表示
    6 分
  • Harmoney targets $1bn loan book as growth accelerates

    Harmoney targets $1bn loan book as growth accelerates
    2026/11/12
    Harmoney Corp Ltd chief executive and managing director David Stevens talked with Proactive about the online lender’s strong start to FY27, growth across Australia and New Zealand, the expansion of its intermediary channel and the company’s target of growing its loan book beyond $1 billion. Stevens explained that Harmoney provides personal and car loans through a fully online model, with loan sizes ranging from $2,000 to $100,000. The company uses risk-based pricing and its proprietary Stellare® platform to automate much of the credit assessment process, allowing eligible customers to receive approvals and funds rapidly. Discussing Harmoney’s recent performance, Stevens highlighted a group loan book of $912 million, representing growth of 9%, including 14% growth in Australia. September also delivered Harmoney’s highest monthly originations in local currency. A major focus is the company’s recently launched Australian intermediary channel. Stevens said the first two partners generated $7 million in loans in less than two months, with around another 10 partners expected to be added over the coming months. Harmoney sees the Australian car lending market as a significant opportunity and is targeting a pipeline of more than $100 million over the next 12 months. The company also reported a net interest margin of 10.3%, credit losses of 3.8% and 90-plus-day arrears of 0.64%. Stevens said Harmoney’s long operating history and use of machine learning have helped the company develop its credit models and maintain risk-based pricing. Looking ahead, Harmoney has reaffirmed FY27 guidance of more than $16 million in cash NPAT and is targeting a loan book above $1 billion by year-end. Stevens said continued growth in the direct business, expansion of the intermediary car lending channel and the scalability of Stellare® would remain central to Harmoney’s strategy. Visit Proactive’s YouTube channel for more interviews and market updates. If you found this video useful, give it a like, subscribe to the channel and enable notifications so you don’t miss future content. #Harmoney #HMY #ASX #ASXStocks #Investing #InvestorNews #Fintech #Lending #PersonalLoans #CarLoans #ConsumerFinance #FinancialTechnology #MachineLearning #AI #Stellare #Australia #NewZealand #FY27 #ProactiveInvestors
    続きを読む 一部表示
    11 分
  • bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions

    bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions
    2026/11/12
    bioAffinity Technologies Inc (NASDAQ:BIAF) President and CEO Maria Zannes spoke with Proactive's Stephen Gunnion about record testing volumes for the company's CyPath Lung test, growing physician adoption and plans to expand its commercial reach. The company performed 235 CyPath Lung tests in October, a monthly record and equivalent to approximately 45% of all tests conducted in the previous quarter. Zannes said the increase reflected both new physicians adopting the non-invasive lung cancer test and greater use among existing customers. She highlighted the role of doctors sharing their experiences with colleagues in driving wider uptake. The company is expanding its sales team, building relationships with patient advocacy groups and pursuing new distribution and healthcare partnerships, including opportunities to reach US veterans. Zannes also discussed the importance of early lung cancer detection, drawing on her own family's experience of the disease. Beyond CyPath Lung, bioAffinity is advancing research into diagnostic applications for asthma and chronic obstructive pulmonary disease (COPD), with the aim of bringing a product to market next year. For more healthcare company interviews, medical technology updates and investor news, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel and enable notifications for future content. Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy #bioAffinityTechnologies #CyPathLung #LungCancerDetection #MariaZannes #LungCancer #EarlyCancerDetection #CancerDiagnostics #MedicalDiagnostics #HealthcareInnovation #MedTech #COPD #Asthma #PrecisionDiagnostics #HealthcareStocks #ProactiveInvestors
    続きを読む 一部表示
    5 分